308 - Population based outcome of HER2 positive early breast cancer in trastuzumab era

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Breast Cancer, Early Stage
Biomarkers
Cancer Aetiology, Epidemiology, Prevention
Presenter Erika Matos
Authors E. Matos, C. Grasic Kuhar, B. Zakotnik
  • Dept. Of Medical Oncology, Institute of Oncology Ljubljana, 1000 - Ljubljana/SI

Abstract

Introduction

About 15% of breast cancer (BC) patients are HER2 positive (HER2+) with high risk of cancer recurrence and death. With adjuvant trastuzumab (T) treatment the risk of reccurence almost halved and the risk of death decreased for one third. Adjuvant treatment with T has been available in Slovenia since August 2005, immediatelly after the first positive trial results.

Aim

Retrospective analysis of relapse free (RFS) and overall survival (OS) in HER2+ BC patients treated with adjuvant trastuzumab in years 2005-09.

Results

Adjuvant T received 317 patients, median age 53 (min 23; max 78) years. Ninety five percent were invasive ductal carcinoma and 97% grade 2/3, 55% were ER positive. Tumor stage was T1 (29%), T2 (48%), T3 (11%), T4 (10%), unknown (2%). N stage was N0 (26%), N1 (50%), N2 (16%), N3 (7%), unknown (1%). All patients recieved adjuvant chemotherapy, 41% anthracycline-based, 48% anthracycline and taxane- based. The median follow-up time was 4.5 (min 0.7; max 6.9) years. There were 66 relapses and 28 deaths. RFS was 98.1, 92.3, 84.2 and 80.8% at 1, 2, 3, 4 years, resp. OS was 99.7, 96.6, 93.4 and 92.5%, at 1, 2, 3, 4 years, resp. The independent prognostic factor for RFS were T stage (HR 1.2 95% CI1.0-1.4) and N stage (HR1.3 (1.1-1.5). Chemotherapy regimen was not found as a prognostic factor for RFS.

Conclusions

This is one of the first reports of the population based results of the adjuvant T treatment. Our results, based on adjuvant T treatment of real-life HER2 + BC patients, are fully comparable to the results obtained in HERA and Joint American study with 4-years RFS around 80%.

Disclosure

All authors have declared no conflicts of interest.